MedKoo Cat#: 561288 | Name: L-703606 Oxalate Salt Hydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-703606 Oxalate is a tachykinin NK1 receptor antagonist.

Chemical Structure

L-703606 Oxalate Salt Hydrate
L-703606 Oxalate Salt Hydrate
CAS#351351-06-9 (Oxalate hydrate)

Theoretical Analysis

MedKoo Cat#: 561288

Name: L-703606 Oxalate Salt Hydrate

CAS#: 351351-06-9 (Oxalate hydrate)

Chemical Formula: C29H31IN2O4

Exact Mass:

Molecular Weight: 598.48

Elemental Analysis: C, 58.20; H, 5.22; I, 21.20; N, 4.68; O, 10.69

Price and Availability

Size Price Availability Quantity
5mg USD 385.00 2 Weeks
25mg USD 1,150.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
L-703606 Oxalate; L703606 Oxalate; L 703606 Oxalate; L-703606 Oxalate salt; L-703,606 Oxalate
IUPAC/Chemical Name
cis-2-(Diphenylmethyl)-N-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine oxalate
InChi Key
VHLWXEPQCNQPNC-CNZCJKERSA-N
InChi Code
InChI=1S/C27H29IN2.C2H2O4/c28-24-14-8-7-13-23(24)19-29-26-22-15-17-30(18-16-22)27(26)25(20-9-3-1-4-10-20)21-11-5-2-6-12-21;3-1(4)2(5)6/h1-14,22,25-27,29H,15-19H2;(H,3,4)(H,5,6)/t26-,27-;/m1./s1
SMILES Code
IC1=CC=CC=C1CN[C@H]2[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)N5CCC2CC5.O=C(O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
L-703606 Oxalate is a tachykinin NK1 receptor antagonist.
In vitro activity:
Moreover, NK-1 receptor antagonist L-703,606 blocked the SP-induced stimulation of proliferation. The results of Western blot analysis showed that L-703,606 attenuated the effects of substance P on NK1R, GSK-3β, and β-catenin expression. Reference: Front Neurosci. 2018 Nov 5;12:806. https://pubmed.ncbi.nlm.nih.gov/30455626/
In vivo activity:
Topical treatment of guinea pigs with L-703,606, either before histamine application or at the time of peak ORI (ocular redness index), effectively reduced ORI and suppressed conjunctival blood vessel dilation, along with decreased eosinophil and neutrophil infiltration, and inflammatory cytokine expression in the conjunctiva, as well as reduced SP levels in the tears. Reference: Ocul Surf. 2022 Oct;26:184-190. https://pubmed.ncbi.nlm.nih.gov/36067981/

Preparing Stock Solutions

The following data is based on the product molecular weight 598.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhang N, Gao D, Liu Y, Ji S, Sha L. Effects of Neuropeptide Substance P on Proliferation and β-Cell Differentiation of Adult Pancreatic Ductal Cells. Front Neurosci. 2018 Nov 5;12:806. doi: 10.3389/fnins.2018.00806. PMID: 30455626; PMCID: PMC6230717. 2. Masterson SP, Li J, Bickford ME. Frequency-dependent release of substance P mediates heterosynaptic potentiation of glutamatergic synaptic responses in the rat visual thalamus. J Neurophysiol. 2010 Sep;104(3):1758-67. doi: 10.1152/jn.00010.2010. Epub 2010 Jul 21. PMID: 20660425; PMCID: PMC2944677. 3. Wang S, Liu L, Blanco T, Ge H, Xia Y, Pang K, Chen Y, Dana R. Therapeutic efficacy of topical blockade of substance P in experimental allergic red eye. Ocul Surf. 2022 Oct;26:184-190. doi: 10.1016/j.jtos.2022.08.008. Epub 2022 Sep 5. PMID: 36067981. 4. Huang H, Zhang X, Fu X, Zhang X, Lang B, Xiang X, Hao W. Alcohol-induced conditioned place preference negatively correlates with anxiety-like behavior in adolescent mice: inhibition by a neurokinin-1 receptor antagonist. Psychopharmacology (Berl). 2018 Oct;235(10):2847-2857. doi: 10.1007/s00213-018-4976-7. Epub 2018 Jul 27. PMID: 30054674.
In vitro protocol:
1. Zhang N, Gao D, Liu Y, Ji S, Sha L. Effects of Neuropeptide Substance P on Proliferation and β-Cell Differentiation of Adult Pancreatic Ductal Cells. Front Neurosci. 2018 Nov 5;12:806. doi: 10.3389/fnins.2018.00806. PMID: 30455626; PMCID: PMC6230717. 2. Masterson SP, Li J, Bickford ME. Frequency-dependent release of substance P mediates heterosynaptic potentiation of glutamatergic synaptic responses in the rat visual thalamus. J Neurophysiol. 2010 Sep;104(3):1758-67. doi: 10.1152/jn.00010.2010. Epub 2010 Jul 21. PMID: 20660425; PMCID: PMC2944677.
In vivo protocol:
1. Wang S, Liu L, Blanco T, Ge H, Xia Y, Pang K, Chen Y, Dana R. Therapeutic efficacy of topical blockade of substance P in experimental allergic red eye. Ocul Surf. 2022 Oct;26:184-190. doi: 10.1016/j.jtos.2022.08.008. Epub 2022 Sep 5. PMID: 36067981. 2. Huang H, Zhang X, Fu X, Zhang X, Lang B, Xiang X, Hao W. Alcohol-induced conditioned place preference negatively correlates with anxiety-like behavior in adolescent mice: inhibition by a neurokinin-1 receptor antagonist. Psychopharmacology (Berl). 2018 Oct;235(10):2847-2857. doi: 10.1007/s00213-018-4976-7. Epub 2018 Jul 27. PMID: 30054674.
1: Minowa S, Tsuchiya S, Someya A, Horie S, Murayama T. Role of neuropeptide receptor systems in vanilloid VR1 receptor-mediated gastric acid secretion in rat brain. Eur J Pharmacol. 2004 Feb 23;486(3):317-24. PubMed PMID: 14985054. 2: Hu D, Chen B, Zhu X, Tao K, Tang C, Wang J. [Substance P up-regulates the TGF-beta 1 mRNA expression of human dermal fibroblasts in vitro]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2002 Jul;18(4):234-6. Chinese. PubMed PMID: 12382579.